Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.

• Yong Ha Chi, Howard Lee, +5 authors Sang Lin Kim
• American journal of cardiovascular drugs : drugs…
• 2011

BACKGROUND AND OBJECTIVES Fimasartan (BR-A-657) is a novel, non-peptide angiotensin II receptor antagonist with a selective type I receptor blockade effect. Two first-in-human studies investigated… (More)

Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.

• Tae Woo Kim, Byoung Wook Yoo, +4 authors Jae Yeol Lee
• Bioorganic & medicinal chemistry letters
• 2012

The discovery, in vitro and in vivo studies of the highly potent AT(1) antagonist 12a (BR-A-657, Fimasartan) antagonists are presented. A series of pyrimidin-4(3H)-one derivatives as losartan… (More)

Development of 3D-QSAR CoMSIA models for 5-(biphenyl-2-yl)-1H-tetrazole derivatives as angiotensin II receptor type 1 (AT1) antagonists.

• Min Ji Choi, Gi Hyun Kwon, +6 authors Jae Yeol Lee
• Bioorganic & medicinal chemistry letters
• 2013

As a development strategy for backups of Fimasartan (1), a comparative molecular similarity indices analysis (CoMSIA) of a set of sixty-five 5-(biphenyl-2-yl)-1H-tetrazole derivatives has been… (More)

• ‹
• 1
• ›